![](/sites/default/files/Fellows/Newton_Kumwenda.jpg)
Elected: 2015
Country (Nationality)
Malawi
Discipline
Medical & Health Sciences
Bio
Prof Kumwenda leads several successful studies; the PEPI-Malawi study was one of the first to establish that post-exposure chemoprophylaxis reduces risk of HIV acquisition. He also led the first HIV-1 phase I vaccine trial in Malawi in 2003 and the multicenter Phase III trial to evaluate the effectiveness of antiretroviral therapy to prevent the sexual transmission of HIV-1 in serodiscordant couples (HPTN052). |